Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.625 +0.075 (+2.94%)

Streaming Delayed Price Updated: 2:56 PM EDT, Mar 23, 2026 Add to My Watchlist

Price and Volume

Volume	3,135,041
Open	2.630
Bid (Size)	2.620 (1,900)
Ask (Size)	2.630 (3,600)
Prev. Close	2.550
Today's Range	2.470 - 2.675
52wk Range	0.6925 - 4.175
Shares Outstanding	28,277,493
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

March 17, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

March 16, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-29.2%	-29.2%
1 Month	-24.6%	-24.6%
3 Month	-35.0%	-35.0%
6 Month	+4.6%	+4.6%
1 Year	+50.9%	+50.9%

More News

ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗

March 10, 2026

Via Stocktwits

Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q4 2025 Results Amid Strategic Expansion ↗

March 10, 2026

Via Chartmill

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 10, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

March 03, 2026

From Corstasis Therapeutics Inc.

Via Business Wire

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

March 03, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

February 24, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Participate in The 2026 Citizens Life Sciences Conference

February 18, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

February 17, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 11, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 11, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

December 19, 2025

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

December 09, 2025

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug ↗

November 25, 2025

Via Stocktwits

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

November 21, 2025

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

November 19, 2025

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

November 18, 2025

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

November 10, 2025

From Esperion Therapeutics, Inc.

Via GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

November 06, 2025

From Esperion Therapeutics, Inc.

Via GlobeNewswire

DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 06, 2025

Via Benzinga

Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗

November 06, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 06, 2025

Via Benzinga

Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

November 06, 2025

Via Benzinga

Frequently Asked Questions

Is Esperion Therapeutics, Inc. - Common Stock publicly traded?

Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?

Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?

The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market

What is the current price of Esperion Therapeutics, Inc. - Common Stock?

The current price of Esperion Therapeutics, Inc. - Common Stock is 2.625

When was Esperion Therapeutics, Inc. - Common Stock last traded?

The last trade of Esperion Therapeutics, Inc. - Common Stock was at 03/23/26 02:56 PM ET

What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?

The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 74.23M

How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?

Esperion Therapeutics, Inc. - Common Stock has 74M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.